Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.45 |
| ▸ | GNRHR | P30968 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5315555 | 0.90 | KDM4E (0.49) | KDM4EPKMHTR4ACHEUTS2R | |
| SCHEMBL5318285 | 0.87 | HTR4 (0.49) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17978289 | 0.86 | HTR4 (0.45) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL8004063 | 0.86 | HTR4 (0.46) | KDM4EPKMHTR4HTR3AHTR3E | |
| SCHEMBL3402337 | 0.85 | HTR4 (0.46) | KDM4EPKMHTR4HTR3AHTR3E | |
| SCHEMBL1502009 | 0.85 | HTR4 (0.46) | KDM4EPKMHTR4HTR3AHTR3E | |
| SCHEMBL3408647 | 0.85 | HTR4 (0.46) | KDM4EPKMHTR4HTR3AHTR3E | |
| SCHEMBL17978155 | 0.84 | HTR4 (0.49) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL19876049 | 0.84 | HTR4 (0.50) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17978193 | 0.84 | HTR4 (0.49) | HTR4HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406434-B | As 5-HT4Amide compounds of receptor agonists | 苏文生命科学有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| EP-3265459-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2018-01-10 | — | — | EP | disclosed |
| WO-2016128990-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| WO-2007068739-A1 | 4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KDM4E 1149/4885PKM 2971/4885HTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.